{"pub": "financialpost", "url": "https://business.financialpost.com/pmn/press-releases-pmn/business-wire-news-releases-pmn/bioasis-announces-filing-of-its-quarter-and-financial-statements-and-mda-for-the-period-ending-august-31-2019", "downloaded_at": "2019-10-25 21:59:51.129332+00:00", "title": "CORRECTING and REPLACING Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending August 31, 2019", "language": "en", "text": "GUILFORD, Conn. \u2014 First paragraph, first sentence of release should read: Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the \u201cCompany\u201d or \u201cBioasis\u201d), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier (\u201cBBB\u201d) and the treatment of central nervous system (\u201cCNS\u201d) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced it has filed its unaudited financial statements and management\u2019s discussion and analysis for the period ended August 31, 2019 (instead of\u2026today announced it has filed its audited annual financial statements and management\u2019s discussion and analysis for the period ended August 31, 2019).\n\nThe corrected release reads:\n\nBIOASIS ANNOUNCES FILING OF ITS QUARTERLY FINANCIAL STATEMENTS AND MD&A FOR THE PERIOD ENDING AUGUST 31, 2019\n\nBioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the \u201cCompany\u201d or \u201cBioasis\u201d), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier (\u201cBBB\u201d) and the treatment of central nervous system (\u201cCNS\u201d) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced it has filed its unaudited financial statements and management\u2019s discussion and analysis for the period ended August 31, 2019. All are available under the Company\u2019s profile on SEDAR at www.sedar.com and on the Company\u2019s website at www.bioasis.us/investors/.\n\nABOUT BIOASIS\n\nBioasis Technologies Inc. is a biopharmaceutical company developing the xB3TM platform, a proprietary technology for the delivery of therapeutics across the BBB and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases. The delivery of therapeutics across the BBB represents the final frontier in treating neurological disorders. The in-house development programs at Bioasis are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders. The company maintains headquarters in Guilford, Conn., United States. Bioasis trades on the TSX Venture Exchange under the symbol \u201cBTI\u201d and on the OTCQB under the symbol \u201cBIOAF.\u201d For more information about the company, please visit www.bioasis.us.\n\nNeither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.\n\nView source version on businesswire.com: https://www.businesswire.com/news/home/20191025005475/en/\n\nContacts\n\nOn behalf of the Board of Directors of Bioasis Technologies Inc.\n\nDeborah Rathjen, Ph.D., Director and President & Chief Executive Officer\n\ndeborah@bioasis.us\n\n+1 203 533 7082", "description": "GUILFORD, Conn. \u2014 First paragraph, first sentence of release should read: Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the \u201cCompany\u201d or \u201cBioasis\u201d), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for...", "authors": [], "top_image": "https://cts.businesswire.com/ct/CT", "published_at": "2019-10-25"}